Biogen Inc. (NASDAQ:BIIB) Stock Rated “Moderate Buy” by Wall Street Brokerages

Shares of Biogen Inc. (NASDAQ:BIIB) have received an average rating of “Moderate Buy” from the thirty-two research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $236.04.

BIIB has been the subject of several research reports. Wedbush upped their price objective on shares of Biogen from $201.00 to $215.00 and gave the company a “neutral” rating in a research note on Thursday, July 30th. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a research note on Monday, June 22nd. Canaccord Genuity Group raised their target price on shares of Biogen from $245.00 to $248.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Citigroup boosted their target price on Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Finally, Stifel Nicolaus set a $242.00 target price on Biogen in a report on Thursday, September 10th.

Hedge Funds Weigh In On Biogen

Institutional investors have recently added to or reduced their stakes in the stock. Reflection Asset Management acquired a new stake in shares of Biogen in the 4th quarter worth $25,000. Bell Investment Advisors Inc purchased a new position in shares of Biogen during the 2nd quarter worth $27,000. MV Capital Management Inc. acquired a new position in shares of Biogen during the 4th quarter valued at about $34,000. SHP Wealth Management acquired a new position in shares of Biogen during the 4th quarter valued at about $39,000. Finally, Cassaday & Co Wealth Management LLC acquired a new position in shares of Biogen during the 1st quarter valued at about $40,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $232.83 on Friday. The firm has a 50-day simple moving average of $218.89 and a 200-day simple moving average of $203.29. The stock has a market capitalization of $34.40 billion, a price-to-earnings ratio of 41.21, a price-to-earnings-growth ratio of 2.53 and a beta of 0.09. The company has a quick ratio of 1.26, a current ratio of 1.87 and a debt-to-equity ratio of 0.39. Biogen has a 52 week low of $138.00 and a 52 week high of $238.24.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share for the quarter, topping the consensus estimate of $2.94 by $0.66. The firm had revenue of $2.74 billion for the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period last year, the firm posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. On average, equities analysts predict that Biogen will post 12.41 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for serious neurological and neurodegenerative diseases. Its research focuses on conditions including multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis and rare neuromuscular disorders.

Biogen’s products include Spinraza (nusinersen) for spinal muscular atrophy, Tysabri (natalizumab) and Tecfidera (dimethyl fumarate) for multiple sclerosis, Qalsody (tofersen) for a genetically defined form of ALS, and Skyclarys (omaveloxolone) for Friedreich’s ataxia.